ViiV Healthcare Receives EU marketing authorization for Triumeq®, a Single-pill Regimen Containing the Integrase Inhibitor “Dolutegravir” Osaka, Japan, September 4, Shionogi - Antiretroviral drug - Document - PDFSEARCH.IO

First Page		Document Content
Date: 2015-01-27 14:49:56 Integrase inhibitors Abacavir Cyclopropanes Purines Antiretroviral drug HIV/AIDS Lamivudine Reverse-transcriptase inhibitor ViiV Healthcare Biology Chemistry Organofluorides		ViiV Healthcare Receives EU marketing authorization for Triumeq®, a Single-pill Regimen Containing the Integrase Inhibitor “Dolutegravir” Osaka, Japan, September 4, Shionogi & Co., Ltd. (Head Office: Osaka; P Add to Reading List Source URL: shionogi616.tew-staging.com Download Document from Source Website File Size: 168,86 KB Share Document on Facebook

	DEPARTMENT OF BIOCHEMISTRY FRONTIERS PROFESSOR KENNETH JOHNSON Roger J. Williams Centennial Professor of Biochemistry, University of Texas, USA DATE DocID: 1pw8Q - View Document
	Human Immunodeficiency Virus (HIV) is a potential precursor to Acquired Immune Deficiency Syndrome (AIDS), which commonly treated with a mixture of reverse transcriptase inhibitors (RTI) and protease inhibitors (PI). Ada DocID: 1pbRe - View Document
	New Zealand Consumer Medicine Information Viramune Tablets and Oral Suspension Nevirapine DocID: 1gvCL - View Document
	Viramune Tablets Viramune Oral Suspension Nevirapine Consumer Medicine Information DocID: 1gtrY - View Document
	ANTIRETROVIRAL PRIORITIES OF THE MEDICINES PATENT POOL DocID: 1fNy0 - View Document